Overview of antimicrobial therapy in intensive care units

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 1, 2011, Pages 97-109

  Textoris, Julien ^a   Wiramus, Sandrine ^a   Martin, Claude ^a   Leone, Marc ^a  

^a HÔPITAL NORD   (France)

Author keywords

antibiotic; de escalation; empiric; sepsis

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MONOTHERAPY; PATIENT ASSESSMENT; PERITONITIS; PHARMACODYNAMICS; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; SEPSIS; TREATMENT DURATION; TREATMENT PLANNING; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 78650650194     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.147     Document Type: Review

References (110)

1. Vincent J, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302(21), 2323-2329 (2009).
2. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34(6), 1589-1596 (2006).
3. Yu VL, Singh N. Excessive antimicrobial usage causes measurable harm to patients with suspected ventilator-associated pneumonia. Intensive Care Med. 30(5), 735-738 (2004).
4. Leone M, Bourgoin A, Cambon S, Dubuc M, Albanèse J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit. Care Med. 31(2), 462-467 (2003).
5. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit. Care Med. 35(2), 379-385; quiz 386 (2007).
6. Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit. Care. 10(3), R78 (2006).
7. Wick JY. Enigmatic, but understandable: empiric therapy. Consult. Pharm. 22(8), 691-694 (2007).
8. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit. Care Med. 35(2), 379-385; quiz 386 (2007).
9. Leone M, Bourgoin A, Cambon S, Dubuc M, Albanèse J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit. Care Med. 31(2), 462-467 (2003).
10. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122(1), 262-268 (2002).
11. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111(3), 676-685 (1997).
12. Lodise TP, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 51(10), 3510-3515 (2007).
13. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388-416 (2005).
14. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin. Infect. Dis. 46(6), 862-867 (2008).
15. Garcin F, Leone M, Antonini F, Charvet A, Albanèse J, Martin C. Non-adherence to guidelines: an avoidable cause of failure of empirical antimicrobial therapy in the presence of difficult-to-treat bacteria. Intensive Care Med. 36(1), 75-82 (2010).
16. Nachtigall I, Tamarkin A, Tafelski S, et al. Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. Crit. Care Med. 37(1), 159-166 (2009).
17. Cabana MD, Rand CS, Powe NR, et al. Why dont physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15), 1458-1465 (1999).
18. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann. Intern. Med. 132(8), 621-630 (2000).
19. Osih RB, McGregor JC, Rich SE, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 51(3), 839-844 (2007).
20. Thom KA, Schweizer ML, Osih RB, et al. Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study. BMC Infect. Dis. 8, 116 (2008).
21. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int. J. Antimicrob. Agents. 2(Suppl. 2), S87-S91 (2008).
22. Schelenz S. Management of candidiasis in the intensive care unit. J. Antimicrob. Chemother. 61(Suppl. 1), i31-i34 (2008).
23. Leone M, Martin C. Starting and stopping antibiotic therapy. In: Controversies in Intensive Care Medicine. Kuhlen R, Moreno R, Ranieri M, Rhodes A (Eds). MWV Medizinisch Wissenschaftliche Verlagsgesellschaft OHG, Berlin, 219-226 (2008).
24. Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit. Care Med. 33(7), 1538-1548 (2005).
25. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36(1), 296-327 (2008).
26. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 36(2), 222-231 (2010).
27. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit. Care Med. 38(4), 1045-1053 (2010).
28. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am. J. Respir. Crit. Care Med. 180(9), 861-866 (2009).
29. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136(5), 1237-1248 (2009).
30. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit. Care Med. 34(11), 2758-2765 (2006).
31. Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infection - an update. Crit. Care Med. 27(4), 836-842 (1999).
32. Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BALconfirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 127(2), 589-597 (2005).
33. Syrjälä H, Broas M, Suramo I, Ojala A, Lähde S. High-resolution computed tomography for the diagnosis of communityacquired pneumonia. Clin. Infect. Dis. 27(2), 358-363 (1998).
34. Lichtenstein DA. Point-of-care ultrasound: infection control in the intensive care unit. Crit. Care Med. 35(Suppl. 5), S262-S267 (2007).
35. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2). S27-S72 (2007).
36. Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch. Intern. Med. 169(16), 1515-1524 (2009).
37. Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with communityacquired pneumonia admitted to the intensive care unit. Clin. Ther. 32(2), 293-299 (2010).
38. Menéndez R, Torres A, Zalacaín R, et al. Guidelines for the treatment of communityacquired pneumonia: predictors of adherence and outcome. Am. J. Respir. Crit. Care Med. 172(6), 757-762 (2005).
39. Fàbregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax 54(10), 867-873 (1999).
40. Torres A, Ewig S, Lode H, Carlet J. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med. 35(1), 9-29 (2009).
41. Ferrer M, Liapikou A, Valencia M, et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin. Infect. Dis. 50(7), 945-952 (2010).
42. Nseir S, Grailles G, Soury-Lavergne A, Minacori F, Alves I, Durocher A. Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensivecare unit admission. Clin. Microbiol. Infect. 16(7), 902-908 (2009).
43. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg. Infect. (Larchmt.) 11(1), 79-109 (2010).
44. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin. Infect. Dis. 50(5), 625-663 (2010).
45. Leone M, Perrin A, Granier I, et al. A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients. Intensive Care Med. 33(4), 726-729 (2007).
46. Vincent J, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302(21), 2323-2329 (2009).
47. C?runtu FA, Benea L. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J. Gastrointestin. Liver Dis. 15(1), 51-56 (2006).
48. van de Beek D, de Gans J. Dexamethasone in adults with community-acquired bacterial meningitis. Drugs 66(4), 415-427 (2006).
49. Arabi Y, Memish ZA, Balkhy HH, et al. Ventriculostomy-associated infections: incidence and risk factors. Am. J. Infect. Control. 33(3), 137-143 (2005).
50. Bouza E, Pérez A, Muñoz P, et al. Ventilator-associated pneumonia after heart surgery: a prospective analysis and the value of surveillance. Crit. Care Med. 31(7), 1964-1970 (2003).
51. Hayon J, Figliolini C, Combes A, et al. Role of serial routine microbiologic culture results in the initial management of ventilatorassociated pneumonia. Am. J. Respir. Crit. Care Med. 165(1), 41-46 (2002).
52. Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BALconfirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 127(2), 589-597 (2005).
53. Blot S, Depuydt P, Vogelaers D, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant Gram-negative bacteria in an intensive care unit. Infect. Control Hosp. Epidemiol. 26(6), 575-579 (2005).
54. Depuydt PO, Blot SI, Benoit DD, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit. Care Med. 34(3), 653-659 (2006).
55. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 130(3), 787-793 (2006).
56. Pea F, Viale P. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter? Crit. Care 13(3), 214 (2009).
57. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J. Antimicrob. Chemother. 28(5), 753-764 (1991).
58. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37(3), 840-851; quiz 859 (2009).
59. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of b-lactam antibiotics. Crit. Care Med. 37(6), 2071-2078 (2009).
60. Boselli E, Breilh D, Rimmelé T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 30(5), 989-991 (2004). (Pubitemid 38639498)
61. Albanèse J, Léone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother. 44(5), 1356-1358 (2000).
62. Georges B, Conil J, Seguin T, et al. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob. Agents Chemother. 53(10), 4483-4489 (2009).
63. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet. 45(8), 755-773 (2006).
64. Moellering R, Mandel G, Bennet J, Dolin R. Principles of anti-infective therapy. In: Mandell, Douglas and Bennets Principles and Practice of Infectious Diseases 5th Edition. Churchill Livingstone, NY, USA (2000).
65. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared to monotherapy in septic shock: a propensitymatched analysis. Crit. Care Med. 38(9), 1773-1785 (2010).
66. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob. Agents Chemother. 54(5), 1742-1748 (2010).
67. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study. Crit. Care Med. 38(8), 1651-1664 (2010).
68. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
69. Shefet D, Robenshtock E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst. Rev. 2, CD004418 (2005).
70. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilatorassociated pneumonia. Crit. Care Med. 36(3), 737-744 (2008).
71. Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum b-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Antimicrob. Agents Chemother. 44(8), 2028-2033 (2000).
72. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit. Care Med. 34(3), 646-652 (2006).
73. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. b-lactam monotherapy versus b lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and metaanalysis of randomised trials. Br. Med. J. 328(7441), 668 (2004).
74. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe bloodstream infections: a population-based assessment. Crit. Care Med. 32(4), 992-997 (2004).
75. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit. Care Med. 32(Suppl. 11), S513-S526 (2004).
76. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7), 885-888 (2003).
77. Depuydt P, Benoit D, Vogelaers D, et al. Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures. Intensive Care Med. 32(11), 1773-1781 (2006).
78. Shurland S, Zhan M, Bradham DD, Roghmann M. Comparison of mortality risk associated with bacteremia due to methicillinresistant and methicillin- susceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 28(3), 273-279 (2007).
79. Zahar J, Clech C, Tafflet M, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin. Infect. Dis. 41(9), 1224-1231 (2005).
80. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit. Care. 10(3), R97 (2006).
81. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med. 33(9), 1983-1987 (2005).
82. Combes A, Luyt C, Fagon J, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 170(7), 786-792 (2004). (Pubitemid 39298995)
83. McNulty C, Logan M, Donald IP, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J. Antimicrob. Chemother. 40(5), 707-711 (1997).
84. Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin. Infect. Dis. 42(Suppl. 2), S72-S81 (2006).
85. Depuydt P, Blot S. Antibiotic therapy for ventilator-associated pneumonia: deescalation in the real world. Crit. Care Med. 35(2), 632-633 (2007).
86. Soo Hoo GW, Wen YE, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 128(4), 2778-2787 (2005).
87. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilatorassociated pneumonia. Crit. Care Med. 32(11), 2183-2190 (2004).
88. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic blind bronchoalveolar lavage fluid. Am. Rev. Respir. Dis. 143(5 Pt 1), 1121-1129 (1991).
89. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am. J. Respir. Crit. Care Med. 162(2 Pt 1), 505-511 (2000).
90. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 128(4), 2706-2713 (2005).
91. Chastre J, Wolff M, Fagon J, et al. Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290(19), 2588-2598 (2003).
92. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 100(6), 1737-1742 (1991).
93. Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapy? Surg. Infect. (Larchmt.) 7(5), 419-432 (2006).
94. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409), 600-607 (2004).
95. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302(10), 1059-1066 (2009).
96. Bouadma L, Luyt C, Tubach F, et al. Use of procalcitonin to reduce patients exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375(9713), 463-474 (2010).
97. Kollef MH. Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. Crit. Care 9(5), 459-464 (2005).
98. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. 29(6), 1109-1115 (2001).
99. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 27(2), 355-362 (2001).
100. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 125(5), 1791-1799 (2004).
101. Lipman J, Boots R. A new paradigm for treating infections: go hard and go home. Crit. Care Resusc. 11(4), 276-281 (2009).
102. Shuman EK, Chenoweth CE. Recognition and prevention of healthcare-associated urinary tract infections in the intensive care unit. Crit. Care Med. 38(Suppl. 8), S373-S379 (2010).
103. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit. Care Med. 31(8), 2228-2237 (2003).
104. Park DR. The microbiology of ventilator-associated pneumonia. Respir. Care. 50(6), 742-763; discussion 763-765 (2005).
105. Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: current concepts and review of the literature. J. Am. Coll. Surg. 208(2), 279-288 (2009).
106. Vallés J, Ferrer R. Bloodstream infection in the ICU. Infect. Dis. Clin. North Am. 23(3), 557-569 (2009).
107. Beer R, Lackner P, Pfausler B, Schmutzhard E. Nosocomial ventriculitis and meningitis in neurocritical care patients. J. Neurol. 255(11), 1617-1624 (2008).
108. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39(9), 1267-1284 (2004).
109. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin. Infect. Dis. 50(5), 625-663 (2010).
110. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 47(3), 303-327 (2008).